Hims & Hers Health is growing up fast—and the market is making it earn every inch
TL;DR
Quick Summary
- Hims & Hers (HIMS) closed 2025 with $2.35B revenue (+59% YoY) and over 2.5M subscribers, but Q4 margins and free cash flow softened.
- 2026 guidance calls for $2.7–$2.9B revenue and $300–$375M adjusted EBITDA, signaling continued growth alongside heavy investment.
- The biggest overhang is GLP-1 compounding scrutiny and legal risk, which keeps attention on durability beyond weight loss.
You've reached your free daily article limit (1/1).
Create a free account to get unlimited access to all articles, market insights, and more.
Register for FreeAlready have an account? Sign in
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
